Dogwood Therapeutics (DWTX) Liabilities and Shareholders Equity (2020 - 2026)

Dogwood Therapeutics (DWTX) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $95.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 1.83% year-over-year to $95.2 million; the TTM figure through Mar 2026 stood at $374.1 million (up 89.68% YoY), while the FY2025 annual figure was $90.2 million, down 4.39% from the prior year.
• Liabilities and Shareholders Equity grew to $95.2 million in Q1 2026 per DWTX's latest filing, from $90.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $97.0 million in Q1 2025 and bottomed at $2.3 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $37.4 million across 5 years, with a median of $9.0 million in 2022.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity tumbled 61.96% — and 2025, when it surged 3929.02%.
• Dogwood Therapeutics' Liabilities and Shareholders Equity stood at $8.4 million in 2022, then plunged by 50.23% to $4.2 million in 2023, then jumped by 2164.06% to $94.3 million in 2024, then decreased by 4.39% to $90.2 million in 2025, then grew by 5.59% to $95.2 million in 2026.
• Business Quant data shows DWTX's Liabilities and Shareholders Equity at $95.2 million in Q1 2026, $90.2 million in Q4 2025, and $92.0 million in Q3 2025.